- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06018766
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome. (INSPO-BOS)
A Randomized, Placebo-controlled Phase 2 Study to Demonstrate the Safety and Efficacy of the Addition of LAM-001 to Standard Immunosuppression Therapy for Chronic Lung Allograft Dysfunction (BOS).
The goal of this clinical trial is to learn about the safety and effectiveness of LAM-001 in patients who have developed bronchiolitis obliterans syndrome (BOS), a form of chronic rejection, after lung transplantation.
The main questions it aims to answer are:
- Is LAM-001 safe in these patients?
- Is LAM-001 effective in slowing BOS progression?
Participants will:
- Be randomly assigned to inhale either LAM-001 or placebo (a look-alike substance that contains no active drug) daily for 48 weeks
- Attend 10 study visits (mixture of in-person and telehealth) over the 48 week period
- Undergo pulmonary function testing, bronchoscopy, lab testing, and physical examination
- Submit weekly home spirometry monitoring
Researchers will compare participants assigned to LAM-001 versus placebo to see if LAM-001 is safely tolerated and to assess the effectiveness of LAM-001 on slowing BOS progression.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chronic rejection, commonly denoted as bronchiolitis obliterans (BO), obliterative bronchiolitis (OB), or bronchiolitis obliterans syndrome (BOS), is the leading cause of death beyond the first year after lung transplantation. Whereas the development of BOS is rare within the first year after lung transplantation, annual increments of approximately 10% are recorded in subsequent years, resulting in a cumulative incidence range of 40-50% within the first five years and 70-80% within 10 years of transplantation.
No current effective treatment for BOS exists. BOS represents the leading cause of morbidity and mortality after lung transplantation, limiting 5-year survival to well below other solid organ transplants. BOS is characterized by an inexorable lung function decline despite currently available immunomodulatory treatments. Sirolimus has been shown to block T-cell proliferative effects induced by cytokines, alloantigens, and mitogens in a dose-dependent manner(4, 5). Oral sirolimus has been shown in small studies to have a beneficial impact on rapidly progressive BOS; however, administration in this patient population has been challenged by a high degree of intolerance with the side effects. The development of LAM-001 for lung transplant related BOS, conceptually a T-cell driven process against transplanted alloantigen, is based on the principal hypothesis that administration of a sirolimus dose to the rejecting lung allograft(s) by inhalation will result in improved efficacy by depositing higher drug concentrations directly within the allograft by inhalation than would be achieved by oral administration due to systemic toxicities associated with oral sirolimus. Because of known reduced systemic bioavailability of LAM-001 compared to oral sirolimus dosing, amelioration of the substantial adverse event profile compared to oral drug is expected. LAM-001 is also expected to reduce serious complication risks by obviating requirements for maintenance and augmented immune drugs used to treat BOS.
The primary objective is to assess the clinical efficacy of LAM-001 in lung transplant recipients with bronchiolitis obliterans syndrome as measured by progression free survival and change in forced expiratory volume in one second (FEV1) over a 48-week period. Another primary objective is to assess the safety and tolerability of LAM-001 in lung transplant recipients with bronchiolitis obliterans syndrome.
Secondary objectives are:
- To determine the impact of LAM-001 on genetic markers of bronchiolitis obliterans syndrome and activation of the mammalian target of rapamycin (mTOR) pathway by measuring chronic lung allograft dysfunction signature gene profiling and mTOR pathway activation in bronchoalveolar lavage fluid
- To determine whether donor-derived cell-free DNA (%ddcfDNA) will predict ongoing injury (versus cessation of BOS progression) by measuring %ddcfDNA in randomized subjects. % ddcfDNA will be correlated with clinical outcome measures of FEV1 change, death, and re-transplantation for both randomized groups.
- To determine the levels of sirolimus in the blood and bronchoalveolar lavage (BAL) fluid, the BAL as a surrogate for levels in the lung.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Steven Hays, MD
- Phone Number: 415-336-4141
- Email: steven.hays@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- Recruiting
- University of California, San Francisco
-
Contact:
- Steven Hays, MD
- Phone Number: 415-353-4141
- Email: steven.hays@ucsf.edu
-
Principal Investigator:
- Steven Hays, MD
-
Principal Investigator:
- Julia Maheshwari, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age > 18 years old
- Recipient of a double pulmonary allograft at least 12 months before study entry
Subjects with clinically diagnosed CLAD-BOS phenotype (all 3 required)
- BOS defined as screening FEV1 between 85-51% of the baseline as defined by the 2 highest FEV1 measures at least 3 weeks apart.
- Diagnosis within 12 months of screening visit.
- FEV1 decline is persistent as defined by decline sustained for > 30 days.
- Currently receiving Standard Immunosuppression. This is defined as a combination of 3 medications including Prednisone, Mycophenolate or Azathioprine, and Tacrolimus or Cyclosporine. The dosing should be stable for 4 weeks prior to screening.
- Absence of oral sirolimus or everolimus treatment for at least 4 weeks prior to screening based on the half-life and resolution of the tissue effects
- Stable enough to enable routine post-transplant bronchoscopy with BAL and biopsy when indicated
- Capable of understanding the purposes and risks of the study
- Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
- Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to study entry
- Women of childbearing potential if sexually active must agree to using highly effective contraception during study and for 90 days after discontinuation of study treatment
- Women of childbearing potential must refrain from breast feeding or donating eggs for the duration of the study and for 90 days after the last dose of study treatment
- Male participants must agree to use a condom during sexual contact with a female of childbearing potential while participating in the study and for 90 days following discontinuation of investigational product use
- Male participants must refrain from donating sperm for the duration of the study and for 90 days after the last dose of study treatment
Exclusion Criteria:
- Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
- Patients with re-transplantation or currently listed for re-transplantation
- Patients with confirmed other causes for loss of lung function, such as acute infection, acute rejection, restrictive allograft syndrome (CLAD - RAS phenotype, see Protocol Specific Definition), etc.
- Patients with acute antibody-mediated rejection at Screening. In this context, clinically stable patients (as judged by the Investigator) with detectable donor-specific antibodies (DSA) levels at the Screening Visit are eligible for the study
- Active acute bacterial, viral, or fungal infection that has not successfully resolved in at least 4 weeks prior to the Screening Visit. Patients with chronic infection or colonization who are clinically stable as per judgement of the investigator are eligible.
- Mechanical ventilation within 12 weeks prior to the randomization
- Patient has baseline resting oxygen saturation of < 89% on room air or use of supplemental oxygen at rest at screening
- Evidence of functional airway stenosis (i.e., bronchomalacia/ tracheomalacia, airway stents, or airways requiring balloon dilatations to maintain patency) with onset after the initial diagnosis of BOS and ongoing at Screening and/or Baseline Visit
- Known hypersensitivity to sirolimus or everolimus
- Currently enrolled in another investigational trial for obstructive chronic lung allograft dysfunction (BOS)
- Patients with chronic renal failure, defined as serum creatinine > 2.5 mg/dL at screening, or requiring chronic dialysis
- Patients with liver disease and serum bilirubin > 3-fold upper limit of normal range or transaminases > 2.5 upper limit of normal range
- Patients with active malignancy within the previous 2 years, including post-transplant lymphoproliferative disorder, except for treated, localized basal and squamous cell carcinomas
- Any history of malignancy likely to result in significant disability or likely to require significant medical or surgical intervention within the next 6 months. This does not include minor surgical procedures for localized skin cancer.
- History of severe allergic reaction to lactose (patients with lactose intolerance are eligible)
- Patients with uncontrolled hypertension
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo administered via dry powder inhaler
|
Experimental: LAM-001
|
LAM-001 administered via dry powder inhaler
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Progression Free Survival (PFS), Level 1
Time Frame: 52 weeks
|
Time to Progression Free Survival (PFS) Level 1, defined as the earliest of the following:
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in FEV1
Time Frame: 48 weeks
|
Change in FEV1 from baseline
|
48 weeks
|
Change in forced expiratory volume in one second/forced vital capacity (FEV1/FVC)
Time Frame: 48 weeks
|
Change in FEV1/FVC from baseline
|
48 weeks
|
Time to Progression Free Survival (PFS), Level 2
Time Frame: 52 weeks
|
Time to Progression Free Survival (PFS) Level 2, defined as the earliest of the following:
|
52 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Quality of Life
Time Frame: 48 weeks
|
Change in Quality of Life as measured by St. George's Respiratory Questionnaire -COPD (SGRQ-C).
The range of scores is 0-100, with the higher scores representing more limitation in quality of life.
|
48 weeks
|
Change in six-minute walk distance (6MWD)
Time Frame: 48 weeks
|
Change in 6MWD from baseline
|
48 weeks
|
Donor-derived cell-free DNA: Ongoing lung injury
Time Frame: 52 weeks
|
Determine whether donor-derived cell-free DNA (%ddcfDNA) will predict ongoing injury (versus cessation of BOS progression) by measuring %ddcfDNA in randomized subjects.
%ddcfDNA will be correlated with clinical outcome measures of FEV1 change, death, and re-transplantation for both randomized groups.
|
52 weeks
|
CLAD signature gene profiling
Time Frame: 3 months post randomization
|
Utilizing the endobronchial brush, we will quantify a metagene, or normalized sum of gene expression, from our previously published airway inflammation gene set, as described in our publication (PMID: 32885581).
The metagene expression will be compared between randomized groups.
|
3 months post randomization
|
mTOR pathway activation
Time Frame: 3 months post randomization
|
Utilizing the bronchioalveolar lavage fluid, we will quantify pS6S235/235 in lymphocytes using flow cytometry, to quantify mTORC1 activity, as previously published (PMID: 36066491).
We will compare pS6S235/235 between randomized groups.
|
3 months post randomization
|
Adverse events
Time Frame: 52 weeks
|
Incidence and severity of treatment emergent adverse events (AE) and serious adverse events (SAE).
|
52 weeks
|
% Reduced donor-derived cell-free DNA
Time Frame: 48 weeks
|
Determine whether the LAM-001 group will have a salutary effect on allograft injury in terms of reduced %ddcfDNA compared to standard therapy by measuring %ddcfDNA values at determined time points and comparing values between the LAM-001 and placebo groups.
|
48 weeks
|
Blood sirolimus levels
Time Frame: Assessed pre-inhalation at in-person study visits over 48 weeks and post-inhalation at 3 months post randomization
|
Measured blood sirolimus levels
|
Assessed pre-inhalation at in-person study visits over 48 weeks and post-inhalation at 3 months post randomization
|
Bronchioalveolar lavage fluid sirolimus levels
Time Frame: 12 weeks
|
Measured bronchioalveolar lavage fluid sirolimus levels
|
12 weeks
|
Airway Hypersensitivity to Treatment
Time Frame: Baseline Study Visit (Week 0)
|
Measurement of FEV1 pre-inhalation and 4 hours following study drug inhalation to determine whether a subject has airway hyperreactivity to the study drug.
|
Baseline Study Visit (Week 0)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Steven Hays, MD, University of California, San Francisco
Publications and helpful links
General Publications
- Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998 Jul;31(5):335-40. doi: 10.1016/s0009-9120(98)00045-9.
- Gillen JR, Zhao Y, Harris DA, LaPar DJ, Kron IL, Lau CL. Short-course rapamycin treatment preserves airway epithelium and protects against bronchiolitis obliterans. Ann Thorac Surg. 2013 Aug;96(2):464-72. doi: 10.1016/j.athoracsur.2013.04.068. Epub 2013 Jun 24.
- Gillen JR, Zhao Y, Harris DA, Lapar DJ, Stone ML, Fernandez LG, Kron IL, Lau CL. Rapamycin blocks fibrocyte migration and attenuates bronchiolitis obliterans in a murine model. Ann Thorac Surg. 2013 May;95(5):1768-75. doi: 10.1016/j.athoracsur.2013.02.021. Epub 2013 Apr 2.
- Zhao Y, Gillen JR, Meher AK, Burns JA, Kron IL, Lau CL. Rapamycin prevents bronchiolitis obliterans through increasing infiltration of regulatory B cells in a murine tracheal transplantation model. J Thorac Cardiovasc Surg. 2016 Feb;151(2):487-96.e3. doi: 10.1016/j.jtcvs.2015.08.116. Epub 2015 Sep 7.
- Bak S, Tischer S, Dragon A, Ravens S, Pape L, Koenecke C, Oelke M, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B. Selective Effects of mTOR Inhibitor Sirolimus on Naive and CMV-Specific T Cells Extending Its Applicable Range Beyond Immunosuppression. Front Immunol. 2018 Dec 17;9:2953. doi: 10.3389/fimmu.2018.02953. eCollection 2018.
- Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010 Jan 1;116(1):210-5. doi: 10.1002/cncr.24696.
- Boers-Doets CB, Raber-Durlacher JE, Treister NS, Epstein JB, Arends AB, Wiersma DR, Lalla RV, Logan RM, van Erp NP, Gelderblom H. Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol. 2013 Dec;9(12):1883-92. doi: 10.2217/fon.13.141.
- Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017 May;25(5):1713-1739. doi: 10.1007/s00520-017-3629-4. Epub 2017 Feb 22.
- Pilotte AP, Hohos MB, Polson KM, Huftalen TM, Treister N. Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors. Clin J Oncol Nurs. 2011 Oct;15(5):E83-9. doi: 10.1188/11.CJON.E83-E89.
- de Oliveira MA, Martins E Martins F, Wang Q, Sonis S, Demetri G, George S, Butrynski J, Treister NS. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol. 2011 Oct;47(10):998-1003. doi: 10.1016/j.oraloncology.2011.08.009. Epub 2011 Sep 3.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Disease
- Bronchial Diseases
- Lung Diseases, Obstructive
- Bronchitis
- Organizing Pneumonia
- Graft vs Host Disease
- Syndrome
- Bronchiolitis
- Bronchiolitis Obliterans
- Bronchiolitis Obliterans Syndrome
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- LAM-001-BOS-CLN01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Transplantation
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
Emory UniversityCompletedLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Heart-Lung TransplantationUnited States
-
Astellas Pharma IncCompletedHeart Transplantation | Lung Transplantation | Pancreas (Including SPK) TransplantationFrance, United Kingdom, Taiwan, Belgium, Italy, Austria
-
Hannover Medical SchoolUnknownExercise Training | Lung Transplantation | Psychotherapy | Heart-Lung Transplantation | "Rehabilitation"Germany
-
University of AlbertaNatera, Inc.; One LambdaRecruiting
-
Universidad Complutense de MadridHospital Universitario 12 de OctubreRecruiting
-
KU LeuvenCompleted
-
Hopital FochCompleted
-
Emory UniversityTerminated
-
Hannover Medical SchoolCorscience, Inc.CompletedLung TransplantationGermany
Clinical Trials on LAM-001
-
OrphAI TherapeuticsRecruitingPulmonary HypertensionUnited States
-
University of Cape TownUniversity of Zimbabwe; University of Zambia; NIMR - Mbeya Medical Research ProgrammeCompletedTuberculosisZambia, Zimbabwe, South Africa, Tanzania
-
Mansoura UniversityCompletedTB - Tuberculosis HIV
-
dr. Stefano NavaRecruitingSleep Apnea Syndromes | Sleep Disorder | Lymphangioleiomyomatosis | Hypopnea SyndromeItaly
-
OrphAI TherapeuticsCompletedAcute Myeloid Leukemia | OncologyUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
Jerry A. Nick, M.D.Enrolling by invitationCystic FibrosisUnited States
-
Shanghai Public Health Clinical CenterUnknownHIV Infections | Tuberculosis | Non-Tuberculous Mycobacterial Pneumonia
-
University of Southern DenmarkOdense University Hospital; University of Ghana; Odense Patient Data Explorative... and other collaboratorsCompletedAcquired Immunodeficiency Syndrome | Tuberculosis, Pulmonary | Human Immunodeficiency Virus (HIV) | Extrapulmonary TuberculosisGhana
-
AI Therapeutics, Inc.No longer available